Search
Close this search box.

Enabling a biomanufacturing industry that is connected, prepared, and always NIIMBL

Enabling a biomanufacturing industry that is connected, prepared, and always NIIMBL

What we do

Advance biopharmaceutical manufacturing

Collaborate on innovative manufacturing technologies that accelerate the ability to bring life-saving and life-enhancing products to market

Solve industry challenges

Help companies find ways to adopt and implement new technologies and approaches, enhancing patient access to medicines and vaccines

Develop the skilled workforce of the future

Cultivate a world-leading biopharmaceutical workforce through novel training and education programs

quotes

Together with our partners...we will ultimately enable life-saving and life-enhancing therapies to be brought to patients more quickly.

Udit Batra, President & CEO, Waters

Play video

Current solicitations

We achieve our mission through an RFx process that aims to advance technical and workforce development projects:

  • Request for Proposal (RFP): A solicitation sent to the entire NIIMBL community that is to result in funding of activities
  • Request for Information (RFI): An open invitation for organizations to share information; not directly associated with funding
  • Request for Applications (RFA): A focused solicitation to particular organizations to submit an application intended to result in funding of activities

See all opportunities
RFP 7.1
RFI 2023.1: Viral Vectors
RFA: NIIMBL eXperience
RFA: Faculty Fellows

RFP 7.1

RFP 7.1 includes both technology development and workforce development topics, with a funding amount of up to $4 million. It is open to current NIIMBL members and to new members by the close of the full proposal deadline.

Project Call 7.1 closed on December 7, 2023. Submissions are now in review.

Learn more

RFI 2023.1: Viral Vectors

RFI 2023.1 – Next-Generation Sequencing (NGS) Method Development Study – aims to promote collaboration among multiple laboratories and industry partners to enhance the reliability, consistency, and understanding of AAV vector properties using NGS-based analysis methods. 

RFI 2023.1 Next-Generation Sequencing (NGS) Method Development Study closed on September 5, 2023.

Learn more

RFA: NIIMBL eXperience

Student applications are currently being accepted for the 2024 NIIMBL eXperience, a week-long program, designed to introduce Black, Latinx, and Indigenous college students to career possibilities in the biopharmaceutical industry. NIIMBL has awarded $370K to five program locations across the country.

Learn more

RFA: Faculty Fellows

NIIMBL is pleased to announce the pilot of a faculty sabbatical in industry program. The NIIMBL Faculty Fellows program provides financial support for faculty or instructional staff at universities and community colleges to pursue a sabbatical either at an industry member (Tier 1 or Tier 2) or at NIIMBL’s Headquarters (NIIMBL HQ) in Delaware to support NIIMBL-led projects.

The NIIMBL Faculty Fellows program closes December 31, 2024.

Learn more

Current solicitations

We achieve our mission through an RFx process that aims to advance technical and workforce development projects:

  • Request for Proposal (RFP): A solicitation sent to the entire NIIMBL community that is to result in funding of activities
  • Request for Information (RFI): An open invitation for organizations to share information; not directly associated with funding
  • Request for Applications (RFA): A focused solicitation to particular organizations to submit an application intended to result in funding of activities

RFP 7.1 arrow down

RFP 7.1

RFP 7.1 includes both technology development and workforce development topics, with a funding amount of up to $4 million. It is open to current NIIMBL members and to new members by the close of the full proposal deadline.

Project Call 7.1 closed on December 7, 2023. Submissions are now in review.

Learn more

RFI 2023.1: Viral Vectorsarrow down

RFI 2023.1: Viral Vectors

RFI 2023.1 – Next-Generation Sequencing (NGS) Method Development Study – aims to promote collaboration among multiple laboratories and industry partners to enhance the reliability, consistency, and understanding of AAV vector properties using NGS-based analysis methods. 

RFI 2023.1 Next-Generation Sequencing (NGS) Method Development Study closed on September 5, 2023.

Learn more

RFA: NIIMBL eXperiencearrow down

RFA: NIIMBL eXperience

Student applications are currently being accepted for the 2024 NIIMBL eXperience, a week-long program, designed to introduce Black, Latinx, and Indigenous college students to career possibilities in the biopharmaceutical industry. NIIMBL has awarded $370K to five program locations across the country.

Learn more

RFA: Faculty Fellowsarrow down

RFA: Faculty Fellows

NIIMBL is pleased to announce the pilot of a faculty sabbatical in industry program. The NIIMBL Faculty Fellows program provides financial support for faculty or instructional staff at universities and community colleges to pursue a sabbatical either at an industry member (Tier 1 or Tier 2) or at NIIMBL’s Headquarters (NIIMBL HQ) in Delaware to support NIIMBL-led projects.

The NIIMBL Faculty Fellows program closes December 31, 2024.

Learn more

See all opportunities

Who we are

Our membership is made up of a diverse set of stakeholders from across the biopharmaceutical manufacturing ecosystem.

Members have the opportunity to collectively revolutionize current biomanufacturing platforms, processes, and educational programs and share in the benefits of these transformative solutions.

No Data Found

June 30, 2023

Woman in protective clothing adjusting a piece of biopharmeutical manfucturing equipment

Why NIIMBL

The NIIMBL ecosystem’s collaborative efforts to accelerate innovative manufacturing technologies help to:

  • Enable lifesaving and life-enhancing therapies to reach patients more quickly
  • Ensure a secure, integrated supply chain
  • Cement the United States’ leadership in the global manufacturing industry
  • Increase the biopharmaceutical industry’s global competitiveness

About biopharmaceuticals and biomanufacturing

About biopharmaceuticals and biomanufacturing

Biopharmaceuticals are medicines that save, sustain, and improve lives.

  • Are manufactured in, extracted from, or derived from biological sources and require complex manufacturing process
  • Treat and prevent some of the most prevalent and debilitating diseases affecting human health, including cancer, diabetes, autoimmune disorders, and bacterial and viral infections, making biopharma one of the most valuable and important business sectors in the United States
  • Play a crucial role in protecting the United States from pandemic diseases
quotes

(NIIMBL) provides a structured space to experiment with approaches that will lead to our ability to rise to today's challenges and build a better future.

Mike Kress, Sr. Vice President Development Sciences and Clinical Supply,
Merck & Co., Inc.

Play video

Become a Member

We offer a variety of membership options that give you the flexibility to choose your organization’s level of engagement based on technology interests and priorities.

Recent news and announcements

NIIMBL Is Now Accepting Applications for the 2024 NIIMBL eXperience Cohort

NIIMBL Launches Viral Vector Program to Improve Access to AAV Gene Therapy

NIIMBL awards $370K for 5 eXperience programs in 2024

NIIMBL Announces RFI for Next-Generation Sequencing Method Development Study

Join Our Mailing List

MailChimp NIIMBL Mailing List Signup
Organization Type
How did you first hear about NIIMBL?